Strand Life Sciences announced that it has entered into an agreement with the U.S. Food and Drug Administration (FDA) to deliver the Genomics Reviewer Desktop (GRD), a solution to enable FDA reviewers to manage and analyze pharmacogenomic data submitted through its Voluntary Exploratory Data Submissions (VXDS) program. The program will enable FDA to integrate analyses needed to reconstruct a sponsor’s interpretation of exploratory biomarker data by using multiple genomics tools and methods. This effort contributes to the development of recommendations for the submission of genomic data.

The software will be integrated with FDA’s ArrayTrack and with other third party analysis software tools.  GRD is built on AVADIS, Strand’s award-winning workflow-driven data analysis and visualization platform that powers software products such as GeneSpring and Sarchitect.  As part of this agreement, FDA has also licensed Strand’s AVADIS software.

Strand Life Sciences